TEVA
梯瓦制药(TEVA.N)在美国开盘时上涨21%，为2022年7月以来的最大涨幅。公司此前与赛诺菲(SNY.O)宣布Duvakitug药物的试验结果，达到治疗溃疡性结肠炎和克罗恩病的主要终点。
时间：2024-12-17 22:31:36 市场： 综合 美股
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 From the Impact-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
时间：2024-11-02 03:05:00 市场： 综合 美股
Teva Prolia® (Denosumab) Biosimilar Candidate Is Accepted for Review by U.S. FDA and EU Ema
时间：2024-10-08 19:00:01 市场： 美股 综合
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients With Debilitating Movement Disorder Tardive Dyskinesia
时间：2024-09-23 13:00:00 市场： 美股 综合
Update: Teva Pharmaceutical Faces Fine in EU for Dismissive Tactics Against Rivals (Updates with additional details from the second paragraph.)Teva Pharmaceutical Industries (TEVA) is expected to face a fine by the European Union antitrust watchdog for being dismissive of a rival multiple sclerosis product competing with Copaxone, multiple sources reported Tuesday, citing people aware of the situation.In 2022, the European Commission found that Teva breached EU antitrust rules by "artificially extending" Copaxone's patent protection and hindering a competing product's market entry by casting doubts on its safety and efficacy.The regulator plans to impose the fine on Teva before the end of current competition commissioner Margrethe Vestager's term in Brussels, although this timeline may be subject to change, Bloomberg reported, citing people familiar with the matter.The European Commission declined Reuters' comment request and Teva didn't immediately respond, Reuters said.Spokespeople f
时间：2024-09-11 01:37:55 市场： 美股 综合
Teva Pharmaceutical Faces EU Fine for Criticizing Rival Multiple Sclerosis Drug, Reuters ReportsPrice: 17.41, Change: -0.40, Percent Change: -2.22
时间：2024-09-11 00:26:32 市场： 美股 综合